EZZ Posts ~$4 Million Cash Inflows in Q3 as Covid-19 Recovery Continues

EZZ is in a solid financial position to build on its growth strategy after a strong Q3 FY22 which has seen the company close the quarter with ~$10.4 million in cash. Genomic-tech firm, EZZ Life Science Holdings (ASX:EZZ) has closed a successful Q3 FY22 with ~$4 million in cash inflows from customers as it gradually …

Embracing Global Health Opportunities

Shared from the 3/31/2022 Financial Review eEdition Life sciences is one of the fastest growing industries in the world, with companies investing heavily in scientific research for the betterment of humankind. The industry comprises companies operating across a broad spectrum; engaging in the research, development and manufacturing of pharmaceuticals, biotechnology-based food and medicines, medical devices, …

EZZ Life Science hosts gastrointestinal health conference in Sydney

By George Tchetvertakov There is a palatable global trend towards greater health consciousness and it’s accelerating, Australian life science company EZZ Life Science (ASX: EZZ) told attendees at its gastrointestinal health conference last week. With the COVID-19 pandemic now ebbing away, albeit gradually, it’s not just Australians that have learned a valuable lesson in health. …

Transformative: EZZ achieves milestone biotech and life sciences listing on ASX

EZZ has achieved a significant milestone after being reclassified on the ASX as the genome-specialist looks to broaden its market share in the biotech and life sciences sector. Aussie-listed genomic-tech firm, EZZ Life Science Holdings (ASX:EZZ) has had its listing changed on the bourse from retail to a pharmaceutical, biotechnology and life sciences company. The …